orforglipron vs tirzepatide Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Orforglipron helps maintain weight loss

Hence, in addition to enhanced blood glucose control, the researchers explained in their paper, GLP-1 receptor agonist therapy may confer additional benefits

If approved for obesity, coverage will be inconsistent

The Legal Framework Health Canada focuses enforcement on companies making therapeutic claims or selling products explicitly for human consumption

GLP-1 therapy is also proven for: semaglutide for PCOS weight management, GLP-1 for visceral fat and belly fat reduction, GLP-1 for cravings and emotional eating, hormone-related weight gain, GLP-1 for osteoarthritis joint relief, semaglutide heart and cardiovascular protection, weight loss for cholesterol improvement, and GLP-1 muscle loss prevention with proper protocol

Lie face down with arms extended overhead (Y) or out to sides (T)